Klinische Forschung Im Medizinischen Versorgungsalltag GbR
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at Klinische Forschung Im Medizinischen Versorgungsalltag GbR is evaluating innovative treatments for Systemic Lupus Erythematosus, aiming to improve disease control and patient quality of life.
- Novel Janus kinase inhibition strategies
- Assessment of patient‑reported outcome measures
- Comprehensive safety profiling in autoimmune disease
Three investigators are collaborating to test a new oral therapy, seeking to demonstrate superior effectiveness compared with standard care.
Musculoskeletal Diseases
At this site, clinicians are conducting research on axial spondyloarthritis to explore better management options for spinal inflammation and pain.
- Evaluation of targeted anti‑inflammatory agents
- Monitoring of radiographic disease progression
- Optimization of functional and mobility outcomes
The study, led by three investigators, compares a novel oral medication with placebo to determine its impact on disease signs and symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinische Forschung Im Medizinischen Versorgungsalltag GbR
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abatacept | 1 | Unknown | 2021-11-05 | 2021-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.